<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168738</url>
  </required_header>
  <id_info>
    <org_study_id>2012.778</org_study_id>
    <nct_id>NCT02168738</nct_id>
  </id_info>
  <brief_title>Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules</brief_title>
  <acronym>AceDoPC</acronym>
  <official_title>Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway
      in human by using 13C labeled molecules.

      The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this
      research is to confirm that some lipidic forms are best carriers for the cerebral
      incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of 13C-DHA in red blood cells</measure>
    <time_frame>At Day 1</time_frame>
    <description>6 hours after product ingestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of 13C-DHA in plasma lipids</measure>
    <time_frame>At Day 1</time_frame>
    <description>6 hours after product ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of 13C-DHA in platelets</measure>
    <time_frame>At Day 1</time_frame>
    <description>6 hours after product ingestion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>13-C labeled PC-DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13-C labeled TG-DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13-C labeled AceDoPC-DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-C labeled AceDoPC-DHA</intervention_name>
    <description>Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months</description>
    <arm_group_label>13-C labeled PC-DHA</arm_group_label>
    <arm_group_label>13-C labeled TG-DHA</arm_group_label>
    <arm_group_label>13-C labeled AceDoPC-DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-C labeled TG-DHA</intervention_name>
    <description>Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months</description>
    <arm_group_label>13-C labeled PC-DHA</arm_group_label>
    <arm_group_label>13-C labeled TG-DHA</arm_group_label>
    <arm_group_label>13-C labeled AceDoPC-DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-C labeled PC-DHA</intervention_name>
    <description>Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months</description>
    <arm_group_label>13-C labeled PC-DHA</arm_group_label>
    <arm_group_label>13-C labeled TG-DHA</arm_group_label>
    <arm_group_label>13-C labeled AceDoPC-DHA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male

          -  Aged of 60 to 70 years

          -  Body Mass Index of 20 to 30 kg/m2

          -  Glycaemic and lipid parameters normal

        Exclusion Criteria:

          -  Smokers more than ten cigarettes/day

          -  Medical history of personal or family dyslipidemia

          -  Medication that could interfere with lipid metabolism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de Recherche en Nutrition Humaine Rh√¥ne-Alpes, 165 chemin du Grand Revoyet,</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.crnh-rhone-alpes.fr</url>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nutrition</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

